Advertisement

Gastroenterologia Japonica

, Volume 18, Issue 3, pp 197–203 | Cite as

“Nonalcoholic steatohepatitis” induced by massive doses of synthetic estrogen

  • Kouichi Seki
  • Yuzo Minami
  • Masahiro Nishikawa
  • Sumio Kawata
  • Shio Miyoshi
  • Yasuharu Imai
  • Seiichiro Tarui
Original Article

Summary

We have noticed that functional disorders of the liver characterized by hepatomegaly and an increase in serum gamma-glutamyl transpeptidase develop in patients with prostatic cancer who are placed under longterm therapy with massive doses of estrogen after castration. We performed laparoscopy in six cases of prostatic cancer with hepatomegaly so that we could study the morphology of the liver. Our findings were as follows. In five, the histological features of the liver biopsies were very similar to those seen in alcoholic hepatitis. In spite of this fact, two of the five had no history of alcohol consumption. Furthermore, in one other case, liver damage resembling alcoholic hepatitis developed during abstinence. The findings in these three cases suggested that long-term, massive doses of synthetic estrogen may lead to liver injury similar to alcoholic hepatitis in nonalcoholics. The ultrastructural findings of the liver cells were also suggestive of the adverse effect of treatment. All cases were negative for hepatitis B surface antigen. Recent reports have demonstrated some nonalcoholics with histological features of the liver indicative of alcoholic hepatitis. This particular condition was termed “nonalcoholic steatohepatitis” by Ludwig et al. It is quite likely that synthetic estrogen is also responsible for “nonalcoholic steatohepatitis” when it is used in massive doses.

Key Words

“nonalcoholic steatohepatitis” alcoholic hepatitis estrogen druginduced liver damage prostatic cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    Marubbio AT, et al: Hepatic lesions of central pericellular fibrosis in morbid obesity and after jejunoileal bypass. Am J Pathol 66: 684, 1976Google Scholar
  2. 2).
    Adler M, et al: Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 67: 811, 1979PubMedCrossRefGoogle Scholar
  3. 3).
    Peters RL, et al: Postjejunoileal-bypass hepatic disease. Its similarity to alcoholic disease. AJCP 63: 318, 1975PubMedGoogle Scholar
  4. 4).
    Falchuk KR, et al: Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology 78: 535, 1980PubMedGoogle Scholar
  5. 5).
    Forbes GB, et al: Liver damage due to perhexilline maleate. J Clin Pathol 32: 1282, 1979PubMedCrossRefGoogle Scholar
  6. 6).
    Pessayre D, et al: Perhexilline maleate-induced cirrhosis. Gastroenterology 76: 170, 1979PubMedGoogle Scholar
  7. 7).
    Lewis D, et al: Liver damage associated with perhexilline maleate. Gut 20: 186, 1979PubMedCrossRefGoogle Scholar
  8. 8).
    Itoh S, et al: Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta Hepato-Gastroenterol 24: 415, 1977Google Scholar
  9. 9).
    Steinberg H, et al: Hepatomegaly with infiltration secondary to cortisone therapy: case report. Gastroenterology 21: 304, 1952PubMedGoogle Scholar
  10. 10).
    Ludwid J, et al: Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proceedings 55: 434, 1980Google Scholar
  11. 11).
    Nöcker J: Sportärtliche Untersuchungsmethodik. in “Lehrbuch d Sportmedizin’. Johann Ambraisins Barth Verlag, Leipzig, 1956, p 20Google Scholar
  12. 12).
    Yanoff M, et al: Peliosis hepatis. An anatomic study with demonstration of two varieties. Arch Pathol 77: 159, 1964PubMedGoogle Scholar
  13. 13).
    Bagheri S, et al: Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury. Annals Internal Med 81: 610, 1974Google Scholar
  14. 14).
    Klatskin G: Toxic and drug-induced hepatitis. in “Diseases of the Liver”, fourth edition. by L Schiff. Lippincott, Philadelphia, 1975, p 604Google Scholar
  15. 15).
    Wattenberg CA: Liver changes and other effects of diethylstilbestrol during treatment of the prostatic cancer. J Urol 55: 631, 1946Google Scholar
  16. 16).
    Konturri M, et al: Effect of oestrogen on liver function of prostatic cancer patients. Brit Med J 4: 204, 1969CrossRefGoogle Scholar
  17. 17).
    Konturri M, et al: Liver damage and estrogen therapy of prostatic cancer. Scand J Urol Nephrol 6: 289, 1972Google Scholar
  18. 18).
    Stirling WC: An analysis of 40 cases of carcinoma of the prostate. J Urol 53: 154, 1945Google Scholar
  19. 19).
    Alcoholic hepatitis: Standardization of nomenclature, diagnostic criteria and diagnostic methodology. in “Diseases of the Liver and Biliary Tract”. Fogarty International Center Proceedings, No 22 GPO, Washington DC, 1976, p 6Google Scholar
  20. 20).
    Seki K, et al: Drug-induced lipidosis (2). Light and electron microscopic studies on the liver. Acta Hepatologica Jpn 12: 266, 1971Google Scholar
  21. 21).
    Rosalki SB, et al: Determination of serum γ-glutamyl transpeptidase and its clinical applications. Ann Clin Biochem 7: 143, 1970Google Scholar
  22. 22).
    Edmondson HA, et al: Sclerosing hyaline necrosis of the liver in the chronic alcoholic. A recognizable clinical syndrome. Annals Internal Med 59: 646, 1963Google Scholar

Copyright information

© The Japanese Society of Gastroenterology 1983

Authors and Affiliations

  • Kouichi Seki
    • 1
  • Yuzo Minami
    • 1
  • Masahiro Nishikawa
    • 1
  • Sumio Kawata
    • 1
  • Shio Miyoshi
    • 1
  • Yasuharu Imai
    • 1
  • Seiichiro Tarui
    • 1
  1. 1.Second Department of Internal MedicineOsaka University Medical SchoolOsakaJapan

Personalised recommendations